Immunovant to host investor webcast at 8:00 am et on wednesday, march 19 to review results from batoclimab myasthenia gravis (mg) and chronic inflammatory demyelinating polyneuropathy (cidp) programs

New york, march 18, 2025 (globe newswire) -- immunovant, inc. (nasdaq: imvt), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on wednesday, march 19th at 8:00 a.m. et to review results from its phase 3 study of batoclimab in mg and initial results from its phase 2b study in cidp.
MG Ratings Summary
MG Quant Ranking